Table 3.
Gel | Version | No. of applications | Gel dosing relative to challenge (h) | Protection vs CG gel (%) | No. of infected macaques/no. of challenged macaques | P value vs CG gel | ||
---|---|---|---|---|---|---|---|---|
ZA/CGb | Prototype | 14 daily | 8 | 78 | 70 | 1/7 | 4/21 | 0.0089 |
ZA/CGb | Prototype | 14 daily | 24 | 53 | 2/7 | |||
ZA/CGb | Prototype | 14 EOD | 24 | 78 | 1/7 | |||
CGb | Prototype | 14 daily | 8–24 | N/A | 9/14 | N/A | ||
ZA/CG | Modified | 14 daily | 24 | 53 | 2/7 | 0.1354 | ||
CG | Modified | 14 daily | 8–24 | N/A | 3/5 | N/A | ||
ZA/CG | Poolc | 14 daily | 24 | 66 | 6/28 | 0.006 | ||
CG | Poold | 14 daily | 8–24 | N/A | 12/19 | N/A |
EOD, every other day; N/A, not applicable.
Published data (6).
Pool of the results obtained with the prototype and modified ZA/CG gel (application adaily or EOD for 14 days, with SHIV-RT challenge 8 to 24 h after the last gel application).
Pool of the results obtained with the prototype and modified CG gel (application daily for 14 days, with SHIV-RT challenge 8to 24 h after the last gel application).